← Back to Compliance

Data Standards for NAMs Regulatory Submissions

Successful regulatory submissions for New Approach Methodologies (NAMs) require adherence to standardized data formats that enable efficient review by regulatory agencies. This guide covers the essential data standards, formatting requirements, and best practices for submitting NAMs data to FDA, EMA, and other global regulators.

SEND: Standard for Exchange of Nonclinical Data

SEND is the CDISC standard specifically designed for nonclinical (animal and in vitro) study data. For NAMs submissions, SEND provides a structured framework for organizing and presenting data from:

• Organ-on-chip studies - Toxicity endpoints, biomarker data, cellular responses
• Organoid experiments - Growth metrics, drug response data, viability assessments
• In vitro assays - Dose-response curves, IC50 values, mechanism data
• Microphysiological systems - Multi-organ interaction data, PK/PD parameters

SEND Implementation Guide (SENDIG)

The SENDIG specifies how to implement SEND for different study types. Key domains relevant to NAMs include:

CDISC Standards Overview

The Clinical Data Interchange Standards Consortium (CDISC) provides a suite of standards that form the backbone of regulatory data submissions:

Foundational Standards

• CDASH - Clinical Data Acquisition Standards Harmonization for data collection
• SDTM - Study Data Tabulation Model for clinical trial data
• ADaM - Analysis Data Model for analysis-ready datasets
• Define-XML - Metadata standard describing dataset contents

Controlled Terminology

CDISC Controlled Terminology ensures consistent vocabulary across submissions. For NAMs, relevant terminology includes:

• Specimen type codes for in vitro samples
• Test codes for novel assay endpoints
• Unit codes for concentration and activity measurements
• Method codes for analytical techniques

Agency-Specific Requirements

FDA Requirements

The FDA's electronic Common Technical Document (eCTD) specifications require:

• SEND format for nonclinical pharmacology and toxicology data
• PDF/A format for study reports and protocols
• Define-XML 2.0 for dataset metadata
• Reviewer's guides explaining data organization

EMA Requirements

The European Medicines Agency follows similar standards with some variations:

• eCTD format aligned with ICH specifications
• SEND data encouraged but not yet mandatory for all submission types
• Additional pharmacovigilance data requirements

PMDA Requirements (Japan)

Japan's regulatory authority has specific requirements including:

• Japanese language summaries required
• eCTD with Japan-specific modules
• Alignment with ICH standards

Best Practices for NAMs Data Submissions

1. Early Engagement - Discuss data format plans with regulators during pre-submission meetings
2. Validation - Run data through OpenCDISC or Pinnacle 21 validators before submission
3. Documentation - Provide comprehensive define files and reviewer's guides
4. Traceability - Maintain clear links between raw data, analysis datasets, and conclusions
5. Version Control - Use standardized naming conventions and track dataset versions

Emerging Standards for NAMs

As NAMs technology evolves, new data standards are being developed:

• MIAME for MPS - Minimum Information About an MPS Experiment
• Organoid Data Standards - Standardized reporting for organoid-based studies
• Digital Twin Data Exchange - Formats for computational model predictions

These emerging standards aim to improve reproducibility and facilitate regulatory acceptance of NAMs data across the global regulatory landscape.